Key result
Low molecular weight heparin is widely used and considered safer than unfractionated heparin for venous thromboembolism in pregnancy, though robust clinical trials are urgently needed.
Why the study?
Does low molecular weight heparin provide safe and effective prophylaxis and treatment for venous thromboembolism in pregnancy compared to unfractionated heparin?
Population
Pregnant and puerperal women requiring prophylaxis or treatment for venous thromboembolism
Comparison
Low molecular weight heparin (LMWH) vs Unfractionated heparin (UFH)
Design
Review
Authors
Loading...
Supports LMWH preference for VTE in pregnancy; leaves open standardized dosing and monitoring pending RCTs.
Does low molecular weight heparin provide safe and effective prophylaxis and treatment for venous thromboembolism in pregnancy compared to unfractionated heparin?
While LMWH is the preferred anticoagulant in pregnancy due to safety and practical advantages over UFH, robust clinical trials are urgently needed to establish standardized dosing and monitoring protocols.
Greer et al. (2005) conducted a review in Venous thromboembolism in pregnancy. Low molecular weight heparin (LMWH) vs. Unfractionated heparin (UFH) was evaluated. Low molecular weight heparin is widely used and considered safer than unfractionated heparin for venous thromboembolism in pregnancy, though robust clinical trials are urgently needed.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: